In the primary prevention group of the DCCT/EDIC study, none out of 67 intensively treated patients carrying the protective INS variant (homo- or heterozygous) developed PDR or DKD with follow-up of 20.4 ± 1.6 years after diagnosis. This evidence concerns the gene INS and diabetic kidney disease.